Market Cap 83.20M
Revenue (ttm) 7.00M
Net Income (ttm) -127.17M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,816.71%
Debt to Equity Ratio 0.00
Volume 282,000
Avg Vol 236,236
Day's Range N/A - N/A
Shares Out 56.60M
Stochastic %K 51%
Beta 1.28
Analysts Sell
Price Target $3.50

Company Profile

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT3789, a selective degrader of SMARCA2 protein for the treatment of advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion; PRT7732, a selective and orally bioavailable SMARCA2 degraders to treat advanced or metastatic solid tumors; and PRT2527, a cyclin...

Industry: Biotechnology
Sector: Healthcare
Phone: 302 467 1280
Address:
175 Innovation Boulevard, Wilmington, United States
pchr
pchr Oct. 4 at 6:38 PM
$PRLD could someone elaborate why are you bullish on this stock? Any incoming catalysts?
0 · Reply
elitechrisvp
elitechrisvp Oct. 1 at 2:06 PM
0 · Reply
LabPsycho
LabPsycho Oct. 1 at 1:50 PM
$PRLD Looks like $PRLD could float back up above $1.69 soon.
1 · Reply
highnihilism
highnihilism Oct. 1 at 1:00 PM
$RMTI Rockwell Medical Trades: 7 | Total $: 215 | 0.08 × 90-Day Avg $: 2.7 K | Call $: 215 | Put $: 0 | Single-Leg: 100% | Multi-Leg: 0% | Contingent: – $PRLD Prelude Therapeutics Trades: 2 | Total $: 215 | 0.68 × 90-Day Avg $: 316 | Call $: 215 | Put $: 0 | Single-Leg: 100% | Multi-Leg: 0% | Contingent: – $EHTH Ehealth Trades: 2 | Total $: 214 | 0.03 × 90-Day Avg $: 7.2 K | Call $: 214 | Put $: 0 | Single-Leg: 100% | Multi-Leg: 0% | Contingent: – $GOOX 2X Long $GOOGL Alphabet Daily Target ETF Trades: 5 | Total $: 805 | 0.12 × 90-Day Avg $: 6.8 K | Call $: 210 | Put $: 595 | Single-Leg: 100% | Multi-Leg: 0% | Contingent: –
0 · Reply
LabPsycho
LabPsycho Sep. 30 at 4:45 PM
$PRLD Clean out this am and prepping for the next leg up?
0 · Reply
StockScanners
StockScanners Sep. 30 at 1:30 AM
$PRLD reached 1.91
0 · Reply
LabPsycho
LabPsycho Sep. 29 at 10:38 PM
$PRLD The animated GIF below provides a 'live' close-up of my molecular dynamics simulation of the PROTAC candidate PRT7732 (shown in yellow). In the simulation, the molecule interacts with residues from two different proteins: cereblon (blue), the E3 ligase component, and SMARCA2 (magenta), the target protein designated for degradation. The purpose of this simulation is to illustrate how one end of the PROTAC binds within a pocket of cereblon, while the other end engages SMARCA2. By bridging these two proteins, the PROTAC promotes a protein–protein interaction that would not normally occur, ultimately leading to ubiquitination and degradation of SMARCA2. The thin lines surrounding each protein highlight residues located within ~2.5 Å of the PROTAC, showing potential points of contact. Importantly, different chemical groups on the PROTAC scaffold (yellow) can be modified to improve binding affinity or to redirect activity toward alternative target proteins.
0 · Reply
Raxothus
Raxothus Sep. 29 at 7:55 PM
EOD CONTINUATION FOLLOW-UP – 09/29/25 Tracking continuation watchlist from today based on intraday highs vs. close ❌ $MTEK – Dumped from 4.27 into the 2s on bad earnings. Full fade, failed continuation. ⚠️ $JUNS – Closed 1.60, reached 1.80 (+12.5%). Slow continuation, needs volume confirmation. ⚠️ $PRLD – Sideways action. No decisive continuation yet. ❌ $ELDN – Closed 2.67, slipped to 2.52. Weak, failed continuation. ⚠️ $GHRS – Sideways action. Neutral, watching for setup. Recap: 5 total → 1 winner, 2 fails, 2 neutral → 20% accuracy Leader: $JUNS (+12.5%) is the only valid continuation candidate, though momentum remains slow. #VWAP #SmallCaps #DayTrading #EODFollowUp #Continuation #SniperSetup #Accountability
0 · Reply
BobBijawklah
BobBijawklah Sep. 29 at 7:52 PM
$PRLD I take it this is a new class of drug that is being developed. The only other two companies that have a similar compound is JNJ and INCY. INCY is the company founded by our current CEO Kris Vahdi. https://preludetx.com/wp-content/uploads/2025/06/Fultang_CALR-ADC_SMARCA_EHA-2025_Oral-Presentation_15Jun2025.pdf
1 · Reply
bailingniao88
bailingniao88 Sep. 29 at 6:31 PM
$PRLD Hi LabPsycho....nice showing of the molecular simulation of the binding of their drug PRT7732 to SMARCA2 for it to work. Good job!
0 · Reply
Latest News on PRLD
Prelude Announces Presentations at 2025 AACR Annual Meeting

Apr 25, 2025, 4:05 PM EDT - 5 months ago

Prelude Announces Presentations at 2025 AACR Annual Meeting


Prelude Therapeutics Announces $25 Million Private Placement

Dec 11, 2023, 9:34 AM EST - 1 year ago

Prelude Therapeutics Announces $25 Million Private Placement


Prelude Therapeutics Reports Full Year 2021 Financial Results

Mar 16, 2022, 7:30 AM EDT - 3 years ago

Prelude Therapeutics Reports Full Year 2021 Financial Results


Why Did Prelude Therapeutics Stock Tumble To 52-Week Low Today?

Oct 7, 2021, 12:55 PM EDT - 4 years ago

Why Did Prelude Therapeutics Stock Tumble To 52-Week Low Today?


Why BofA Is Turning Bullish On Prelude Therapeutics

Jul 27, 2021, 12:32 PM EDT - 4 years ago

Why BofA Is Turning Bullish On Prelude Therapeutics


pchr
pchr Oct. 4 at 6:38 PM
$PRLD could someone elaborate why are you bullish on this stock? Any incoming catalysts?
0 · Reply
elitechrisvp
elitechrisvp Oct. 1 at 2:06 PM
0 · Reply
LabPsycho
LabPsycho Oct. 1 at 1:50 PM
$PRLD Looks like $PRLD could float back up above $1.69 soon.
1 · Reply
highnihilism
highnihilism Oct. 1 at 1:00 PM
$RMTI Rockwell Medical Trades: 7 | Total $: 215 | 0.08 × 90-Day Avg $: 2.7 K | Call $: 215 | Put $: 0 | Single-Leg: 100% | Multi-Leg: 0% | Contingent: – $PRLD Prelude Therapeutics Trades: 2 | Total $: 215 | 0.68 × 90-Day Avg $: 316 | Call $: 215 | Put $: 0 | Single-Leg: 100% | Multi-Leg: 0% | Contingent: – $EHTH Ehealth Trades: 2 | Total $: 214 | 0.03 × 90-Day Avg $: 7.2 K | Call $: 214 | Put $: 0 | Single-Leg: 100% | Multi-Leg: 0% | Contingent: – $GOOX 2X Long $GOOGL Alphabet Daily Target ETF Trades: 5 | Total $: 805 | 0.12 × 90-Day Avg $: 6.8 K | Call $: 210 | Put $: 595 | Single-Leg: 100% | Multi-Leg: 0% | Contingent: –
0 · Reply
LabPsycho
LabPsycho Sep. 30 at 4:45 PM
$PRLD Clean out this am and prepping for the next leg up?
0 · Reply
StockScanners
StockScanners Sep. 30 at 1:30 AM
$PRLD reached 1.91
0 · Reply
LabPsycho
LabPsycho Sep. 29 at 10:38 PM
$PRLD The animated GIF below provides a 'live' close-up of my molecular dynamics simulation of the PROTAC candidate PRT7732 (shown in yellow). In the simulation, the molecule interacts with residues from two different proteins: cereblon (blue), the E3 ligase component, and SMARCA2 (magenta), the target protein designated for degradation. The purpose of this simulation is to illustrate how one end of the PROTAC binds within a pocket of cereblon, while the other end engages SMARCA2. By bridging these two proteins, the PROTAC promotes a protein–protein interaction that would not normally occur, ultimately leading to ubiquitination and degradation of SMARCA2. The thin lines surrounding each protein highlight residues located within ~2.5 Å of the PROTAC, showing potential points of contact. Importantly, different chemical groups on the PROTAC scaffold (yellow) can be modified to improve binding affinity or to redirect activity toward alternative target proteins.
0 · Reply
Raxothus
Raxothus Sep. 29 at 7:55 PM
EOD CONTINUATION FOLLOW-UP – 09/29/25 Tracking continuation watchlist from today based on intraday highs vs. close ❌ $MTEK – Dumped from 4.27 into the 2s on bad earnings. Full fade, failed continuation. ⚠️ $JUNS – Closed 1.60, reached 1.80 (+12.5%). Slow continuation, needs volume confirmation. ⚠️ $PRLD – Sideways action. No decisive continuation yet. ❌ $ELDN – Closed 2.67, slipped to 2.52. Weak, failed continuation. ⚠️ $GHRS – Sideways action. Neutral, watching for setup. Recap: 5 total → 1 winner, 2 fails, 2 neutral → 20% accuracy Leader: $JUNS (+12.5%) is the only valid continuation candidate, though momentum remains slow. #VWAP #SmallCaps #DayTrading #EODFollowUp #Continuation #SniperSetup #Accountability
0 · Reply
BobBijawklah
BobBijawklah Sep. 29 at 7:52 PM
$PRLD I take it this is a new class of drug that is being developed. The only other two companies that have a similar compound is JNJ and INCY. INCY is the company founded by our current CEO Kris Vahdi. https://preludetx.com/wp-content/uploads/2025/06/Fultang_CALR-ADC_SMARCA_EHA-2025_Oral-Presentation_15Jun2025.pdf
1 · Reply
bailingniao88
bailingniao88 Sep. 29 at 6:31 PM
$PRLD Hi LabPsycho....nice showing of the molecular simulation of the binding of their drug PRT7732 to SMARCA2 for it to work. Good job!
0 · Reply
LabPsycho
LabPsycho Sep. 29 at 5:49 PM
$PRLD I will try to clarify. If one zooms in on the molecular dynamic simulation, they can see with atomic resolution residues of the protein that may interact with various moieties of the drug. Here just for kicks, I show the putative (lots of guessing from patent and literature research which of the hundreds of variants PRT7732 might be but I think is is at least a reasonable approximation) showing ASN, TYR and LEU in close proximity to the drug. One could refine the drug further to enhance or repel such interactions depending on the goal. Big advantage for me of doing these simulations is spilling pizza grease on the keyboard rather than in the test tubes - Ha
1 · Reply
LabPsycho
LabPsycho Sep. 29 at 2:26 PM
$PRLD Several potential milestones upcoming this year per recent quarterly report. Wild price movement this morning after huge gain last Friday + big increase in volume = clean out before the next run?
0 · Reply
exp8triot
exp8triot Sep. 29 at 1:38 PM
$PRLD big volume
0 · Reply
Dizzier47
Dizzier47 Sep. 29 at 1:36 PM
$PRLD holding until lambo
0 · Reply
LabPsycho
LabPsycho Sep. 29 at 11:23 AM
$PRLD @Dizzier47 Ha. Molecular dynamic simulations (MDS) can help accelerate drug discovery and development. The old way would be to synthesize a drug then do lots of trial and error at the benchtop / cell culture screening = lots of time and $$$. If the 3D crystal structure of the target protein is known, one can design drugs, in this case a molecular glues, and do a lot of prescreening / refinement 'in silico' (in the computer. The current limitation is the computing power required. That is why I have been encouraging some of these companies I have posted MDS on their drugs to hook up with $NVDA to use their GPU and other incredible resources to accelerate this process 10,000 X faster than what I can do.
0 · Reply
SadyK189
SadyK189 Sep. 29 at 1:35 AM
Top Stocks to watch next week 2 / 2: $APDN $SOPH $DFLI $PRLD $STKH APDN: Getting up on 4hours chart. Key support at 3.40 - 3.70. Currently at 4.49. Next key level to test lies at 5.20 - 5.60 PRLD: Looking good on daily chart. Key support at 1.15 - 1.30. Next key lest to test 1.90 - 2.05. Currently at 1.53 DFLI: Still looking good on 4hours chart. Key support at 0.38 - 0.41. It can test 0.55 - 0.5850 zone again. Currently at 0.46 STKH: Good close of 4hours candle. 4.15 - 4.45 is acting as key support zone. Next key level to test is 6.75 - 7.15. Currently at 5.83 SOPH: Getting up on daily chart. Key support at 3.20 - 3.50. Next key level to test is 4.8 - 5.15. It may take sometime though. Currently at 4.13
0 · Reply
LabPsycho
LabPsycho Sep. 28 at 7:51 PM
$PRLD Part 1. I performed a brief molecular dynamics (MD) simulation (see post Below) to explore a putative structure of the protein degrader PRT7732 in partial complex with Cereblon and SMARCA2. PRT7732, a degrader currently in clinical trials, was initially positioned near the SMARCA2 bromodomain and at the thalidomide-binding domain (TBD) of Cereblon, then solvated and subjected to periodic boundary conditions. Over the course of the simulation, PRT7732 progressively engaged more deeply with the SMARCA2 binding pocket, appearing to stabilize interactions that bring Cereblon and SMARCA2 into closer proximity. These observations suggest a structural basis for PRT7732-mediated recruitment of SMARCA2 to the CRL4 E3 ubiquitin ligase complex, thereby priming SMARCA2 for targeted degradation.
1 · Reply
LabPsycho
LabPsycho Sep. 28 at 7:50 PM
$PRLD PART 2. Molecular modeling ensembles were created in part by LabPsycho’s Artificial Artificial Intelligence A.^2 I. [exponentially greater than A.I.] and dynamically simulated by @LabPsycho using VMD and NAMD software developed at the University of Illinois, Urbana-Champaign Theoretical and Computational Biophysics Group. GPU based simulations were also performed in OpenMM and Google Colab using a T4 GPU. Starting molecular ensemble based in part on LabPsycho’s A.^2 I. and crystallographic structures from https://www.rcsb.org/. PDB IDs: 6HAX, 6BNB, 6TTU, 9D11 Eclectic representative structure of PRT7732 approximated from: BRM AND BRG1 TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE https://patentscope.wipo.int/search/en/WO2025184459
1 · Reply
Dizzier47
Dizzier47 Sep. 27 at 9:02 PM
$PRLD give me 2 give me 4 give me 8
0 · Reply
Doozio
Doozio Sep. 27 at 4:07 PM
$PRLD it was always 🐒🍌🧠⏰♾️ n Roger got lots of room to run.
0 · Reply
StockScanners
StockScanners Sep. 27 at 4:15 AM
$PRLD keep watch if this holds above 1.41
0 · Reply
BobBijawklah
BobBijawklah Sep. 26 at 8:10 PM
$PRLD I think you have to look at who runs the company who are the major investors. Baker brothers bought at ipo in the 20s . Most of their biotechs are winners. made nice returns on so many of their stocks sgen mdgl ect ect. Vahdi is a stud of CEO the fact that no one is selling and vadhi has been buying is a no brainer . They have the cash to get through next year their pipeline of preclinical is probably way way bigger than most would imagine. The action of price means to me that the data from PRT7732 is just as good as the preclincal. Value this at a billion dollars with the outstanding shares and the price would be 20 dollars a share. 2 billion 40 so on and so forth. Is it plausible yes. If the data holds out this is going to triple overnight
1 · Reply